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Abstract Cardiovascular disease (CVD) mortality is a
leading cause of death in adult chronic kidney disease
(CKD), with exceptionally high rates in young adults,
according to the Task Force on Cardiovascular Disease.
Recent data indicate that cardiovascular complications are
already present in children with CKD. This review
summarizes the current literature on cardiac risk factors,
mortality and morbidity in children with CKD.
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Learning objectives:
1. To review recent data on the epidemiology of CVD in
children with CKD
2. To understand the mechanisms of cardiovascular
abnormalities in pediatric CKD
3. To review recent advances in the diagnosis and clin-
ical presentation of cardiovascular complications in
children with CKD
4. To outline current understanding in the strategies to
prevent progression of CVD in children with CKD.
Cardiovascular mortality and morbidity
The survival of children with CKD in the U.S. remains low:
for children on dialysis the lifespan is 40–60 years less and
for transplant patients, about 20–25 years less than that of
an age- and- race-matched US population [1, 2]. The most
likely cause of this is increased cardiovascular mortality
due to the development of accelerated ischemic heart
disease and premature dilated cardiomyopathy. The evi-
dence comes from studies of young adults who developed
renal failure during childhood. Oh et al. [3] analyzed the
outcome of 283 young adults with childhood onset CKD
between 1970 and 1997. Fifty percent of the deceased
patients had died of cardiovascular or cerebrovascular
events. Groothoff et al. [4] conducted a national retrospec-
tive and prospective cross-sectional study to evaluate the
late physical, social and psychological effects of renal
insufficiency (LERIC) in all Dutch children who started
renal replacement therapy between 1972 and 1992. Of 381
patients, 85 had died. Cardiovascular disease was the most
common cause of death and accounted for 41% of all
deaths. Cerebrovascular accident, congestive heart failure,
myocardial infarction and cardiac arrest (respectively) were
the most common causes of cardiac death. Similar analysis
of long-term survival from the Australia and New Zealand
Dialysis and Transplant Registry [5] of all children and
adolescents who were under 20 years of age when renal
replacement therapy commenced (study period was
40 years) showed mortality rates 30 times higher than in
the age-matched general population; CVD was the most
common cause of death (45%).
Cardiovascular death happens not only in later life, but
also in childhood CKD. In the general pediatric population,
the incidence of annual death due to cardiac disease is less
than 3%. Yet annual reports from the United States Renal
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CVD has remained the second most common cause of
death in children on chronic dialysis or after transplanta-
tion, accounting for approximately 20–25% of all deaths.
Parekh et al. [6], using the USRDS database, performed a
detailed cross-sectional analysis to evaluate the risk of a
cardiac death in children and young adults (age 0–30 years)
and to identify factors potentially associated with CVD
mortality. A total of 1,380 deaths between 1990 and 1996
were analyzed. There were 311 cardiac deaths (22.5% of
the total). Cardiac deaths in children and young adults in
whom ESRD developed during childhood were approxi-
mately 1,000 times more frequent than in the general
pediatric population. Of the specific categories of cardio-
vascular deaths, cardiac arrest was the most common cause
in each of the age groups, followed by arrhythmia and
cardiomyopathy. These causes of cardiac death are different
from those of adults. In adults, coronary artery disease and
chronic congestive heart failure are the leading causes of
CVD mortality and, as shown by Parekh et al. [6], these
causes are extremely rare in children and adults younger
than 30 years of age. The incidence of cardiac arrest in the
youngest age group (0–4 years) was five to ten times higher
than in other age groups, perhaps, as noted by the authors, a
reflection of the difficulty of ascertaining the true cause of
death in young children. Some of these young children
might have died from other co-morbid conditions such as
congenital disorders that are not included in the USRDS
database.
The high rate of sudden death in children, especially in
infants with ESRD, is poorly understood and warrants
further investigation. In adults, sudden death is often a
result of fatal arrhythmias due to acute ischemia of
preexisting atherosclerotic disease. It is believed that
arrhythmias are also the likely cause of most cases of
sudden cardiac death (SCD) in children. However, the
origin of acquired malignant arrhythmias in children is
unlikely to be an atherosclerotic lesion. Dilated, especially
hypertrophic, cardiomyopathies are a leading cause of SCD
in children [7]. The macroscopic and microscopic structural
abnormalities in cardiomyopathies involve fibrosis and
cellular hypertrophy prone to produce an electrical insta-
bility with resultant arrhythmias. Ischemia of small coro-
nary vessel disease secondary to medial hypertrophy might
result in dispersion of repolarization properties and arrhyth-
mia from re-entrant or autonomic mechanisms. As we
discuss in more detail below in this review, children with
CKD develop left ventricular hypertrophy (LVH), which is
frequently severe, especially in children on prolonged
dialysis therapy [8, 9]. It is currently unknown if LVH in
young patients with CKD is characterized by structural
abnormalities similar to familial or idiopathic hypertrophic
cardiomyopathies associated with SCD. Whether LVH of
children with ESRD can contribute to increased SCD is
also not known. Another possibility for deadly arrhythmias
in children with ESRD is acute changes in the cardiac
extra- or intracellular ionic milieu, especially involving
abnormalities of sodium- and potassium-based repolariza-
tion currents.
Because the causes of cardiac death in children and
adults are different, it is not surprising that none of the
traditional or uremia-related risk factors for adult athero-
sclerotic CVD predicted cardiac death in the study by
Parekh [6]. One of the examples presented in this paper is
the effect of race on CVD death. In adults with ESRD,
white males are at higher risk for CVD mortality. In
contrast, black children as shown by Parekh et al. [6]
appear to have an increased risk for cardiac death. Another
important observation of this study is that transplant
recipients had 78% lower risk of cardiac death than dialysis
patients. However, the authors pointed out that the CVD
mortality rate in transplanted patients was still significantly
higher (approximately ten times) than in the general
pediatric population.
The analysis of cardiac morbidity in children on chronic
dialysis performed by Chavers et al. [10] has confirmed that
cardiac disease in children is different from adults. A total
of 1,454 Medicare incident pediatric (0–19 years) dialysis
patients were identified from 1991 to 1996. Among them,
452 (31.2%) developed a cardiac-related event. Arrhythmia
was most common (19.6%), followed by valvular disease
(11.7%), cardiomyopathy (9.6%) and cardiac arrest (3%).
Ischemic heart disease was extremely rare in these children.
Risk factors for cardiovascular disease
The risk factors and pathogenic mechanisms of develop-
ment of CVD in young adults who had onset of CKD in
childhood are better understood than are those producing
cardiac morbidity and mortality in children. The conven-
tional thinking is that two groups of risk factors are
responsible for accelerated CVD in adults with CKD
(Table 1).
First, as compared to the non-uremic population, there is
an over-representation in uremic patients of classical risk
factors, e.g., diabetes, hypertension and hyperlipidemia. A
majority of the adults who develop ESRD do so as a
complication of diabetes or generalized atherosclerosis.
Often cardiac disease antedates the onset of CKD in these
patients. Unfortunately, children with CKD share with
adults a similar high prevalence of risk factors for adult-
type atherosclerotic CVD. It is also troubling that the
frequencies of these traditional risk factors have not
changed over last decade. The North American Pediatric
Renal Trials Collaborative Studies (NAPRTCS) data dem-
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(48%) and persists (50–75%) in uremic children [11–14].
Dyslipidemia is found in 70 to 90% during chronic dialysis
[15–18]. Successful renal transplantation leads to a dra-
matic improvement in renal function and elimination of
many risk factors for atherosclerotic CVD that were present
while on dialysis. However, transplant recipients are not
free from multiple complications, and transplantation may
amplify some of the traditional risk factors. Indeed, the
prevalence of hypertension in pediatric renal allograft
recipients is between 50–80% [19–21]. Also, hyperlipid-
emia may not disappear after renal transplantation; the
reported prevalence is above 50% [22–24]. The NAPRTCS
data also show that the rate of obesity, another CV risk, is
increasing in children with ESRD at the time of transplan-
tation (12.4% after 1995 vs. 8% prior to 1995) [25]. Single-
center study data indicate that the number of obese patients
can double at 1 year after transplantation [26].
Second, there is a multitude of uremia-related risk factors
for atherosclerotic CVD. In adults with CKD, an increased
homocysteine level appeared to be an independent risk
factor for CVD morbidity and mortality [27–29]. Anemia
has been linked to negative CVD outcome [30]. Hyper-
phosphatemia with increased calcium-phosphorus product
constitutes a risk for cardiovascular calcification, cardiac
ischemia and adverse cardiovascular outcomes [31, 32].
Elevated serum C-reactive protein (CRP), a marker of
systemic inflammation, has been found to be a strong
predictor of cardiac morbidity and cardiac death in CKD
patients [33]. Another marker of inflammation, IL-6, has
been associated with increased cardiac morbidity in adults
with CKD [34, 35]. The role of systemic inflammation in
CKD has been reviewed recently elsewhere [36]. Inflam-
mation is directly linked to oxidative stress, which is now
considered as a hallmark of uremia [37]. Asymmetric
dimethylarginine (ADMA), an endogenous inhibitor of
nitric oxide synthase and a marker of oxidative stress, has
been extensively evaluated in patients with CKD by Zoccali
et al. [38]. The authors demonstrated that elevated ADMA
per se was responsible for a 52% higher risk of death and
for a 34% higher risk of cardiovascular events in dialysis
patients [39]. Another subset of novel CVD risk factors is
adipokines. Adipokines, leptin and adiponectin, are the
products of adipose tissue involving in regulation of lipid
and glucose metabolism. Abnormal adipokines are strongly
linked to insulin resistance, a known CV risk in CKD [40].
It has been determined that lower plasma adiponectin
concentration independently predicts increased CVD mor-
bidity and mortality in adults with ESRD [41]. Clinical
Practice Guidelines for Cardiovascular Disease in Dialysis
Patients extensively reviewed the current literature on CVD
biomarkers, and the reader is referred to this publication for
more information [42]. As in adults, in children with CKD
many of these risk factors are very prevalent (Table 2).
Recent studies in adults on chronic hemodialysis place a
malnutrition-inflammation complex at the center of a
debate about the role of traditional and non-traditional risk
factors for poor cardiovascular outcome. This issue
emerged after publication of a series of articles, summa-
rized in the review by Nurmohamed and Nube [60],
describing the phenomenon of “reverse epidemiology.”
The studies have shown that in adults on chronic
hemodialysis low blood pressure, low body mass index
(BMI), low serum cholesterol and low serum homocys-
teine are often correlated with an unfavorable clinical
Table 1 Cardiovascular risk factors in chronic kidney disease in
adults
Traditional CKD-related
Older age Decreased GFR
White race Proteinuria
Male gender Peripheral renin-angiotensin-
aldosterone activity
Hypertension Abnormal calcium and phosphorus
↑ LDL Cholesterol Dyslipidemia
↓ HDL Cholesterol Hypoalbuminemia
Diabetes mellitus Hemodynamic overload
Tobacco use Anemia
Physical inactivity Thrombogenic factors
Psychosocial stress Hyperhomocysteinemia
Family history of CVD Oxidative stress
LVH Infection (Chlamydia pneumoniae)
Obesity Chronic inflammation
Table 2 Prevalence of risk factors for CVD in children with CKD
Risk factors CRI
a (%) Dialysis
b (%) Transplant
c (%) References
Hypertension 48 52–75 63–81 11
a,1 2 –14
b,1 9 –21
c
Dyslipidemia 25–53 33–87 55–84 15
a,1 5 –18
a, b,2 2 –24
c
Anemia 48 40–67 32–64 43
a,4 4 –47
b,4 8 –51
c,
Hyperparathyroidism 32.6–43.7 58 – 43
Hyperhomocysteinemia 87–92 25–100 52
c,5 3
b, c,5 4
c,5 5
b
↑ CRP 76 16 56
b,57
c
Hypoalbuminemia – 40–60 – 43
b,4 4
b,5 8 –59
b
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are correlated with an unfavorable outcome in the general
population and patients with CKD not yet on dialysis, in
hemodialyzed patients, mild hypertension, hypercholester-
olemia and being overweight appear to be protective and
associated with an improved survival. It has been
speculated that a malnutrition-inflammation-atherosclerosis
complex underlies, at least partly, the phenomenon of
reverse epidemiology, since malnutrition causes a low
BMI, hypocholesterolemia and low serum homocysteine
levels.
Mechanisms of cardiovascular disease in chronic kidney
disease
There are two parallel processes involved in the develop-
ment of CVD in CKD patients (Fig. 1).
The first is cardiac remodeling leading to hypertrophy of
the left ventricle (LV) as a response to mechanical or hemo-
dynamic overload. Two different patterns of LV remodeling
can produce increase in LV mass (LVM) [61]. The
concentric LV remodeling and hypertrophy may be the
results of pressure overload as occurs with hypertension,
whereas eccentric LVH may be related to volume and
sodium retention, anemia and arteriovenous shunt. The
patterns of sarcomere formation induced by pressure or
volume overload are distinct. Pressure-induced concentric
LVH is characterized by a parallel addition of sarcomeres
resulting in the increase of cross-sectional area and diameter
of the myocytes. Increase in LVM in this case is obtained by
a marked increase in wall thickness with a less evident
increase in the LV cavity that yields an elevated relative wall
thickness and concentric LVH. From the physiological view,
increased systolic blood pressure (BP) and pulse pressure,
due to increased peripheral resistance and arterial stiffness,
are the principal factors opposing LVejection and leading to
an increased LV workload and concentric LVH. An increase
in LVM can also be obtained by an increase in the LV cavity
with a symmetric increase in wall thickness to maintain the
ratio between the wall thickness and LV transversal radius
(relative wall thickness) normal, producing eccentric LVH.
In this case, the addition of sarcomeres occurs mainly in
series resulting in longitudinal cell growth. In the transition
to maladaptive LVH, LV dilatation becomes disproportional
to wall thickness, with myocytes elongated without an
increase in diameter.
Experimental models of cardiac hypertrophy support the
theory that mechanical stress due to either pressure or
volume overload is a trigger for activation of other multiple
Fig. 1 Cardiovascular disease
in chronic kidney disease
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factors include a local overexpression of the renin-angio-
tensin-aldosterone system (RAAS), adrenergic system,
inflammatory cytokines and other autocrine and paracrine
mechanisms. In patients with CKD, these mechanisms
might be activated independently of hemodynamic overload
since uremia per se is associated with an alteration in
multiple humoral factors [63, 64]. With time, a maladaptive
phase of LVH develops, characterized by decreased
capillary density, decreased coronary reserve and subendo-
cardial perfusion, a tendency to arrhythmia, and the
development of myocardial fibrosis. All this leads to
myocyte death and, finally, to diastolic and systolic
dysfunction.
The second process involves vascular injury. Exposure
to CV risk factors results in vascular changes, including
atherosclerotic and arteriosclerotic processes and vascular
calcification.
Atherosclerosis refers to the process of plaque formation
or atheroma development. The process of atheroma
formation begins with an accumulation of lipid-containing
foam cells (macrophages) in the vascular intima and
evolves into successive structures that penetrate the
vascular wall and include lipids, smooth muscle cells and
collagen fibers [65]. Calcification is an intrinsic part of the
process and generally involves the intima. Atherosclerotic
lesions have a patchy distribution along the length of the
artery and cause local stenoses and occlusions. Recently,
endothelial progenitor cells (EPCs) have been identified as
contributing to angiogenesis [66]. The EPC number has
been shown to be reduced in patients with CVD, leading to
speculation that atherosclerosis may be caused by a
consumptive loss of the endothelial repair capacity. Animal
experiments have shown that EPCs reendothelialise injured
vessels and that this reduces neointimal formation, con-
firming that EPCs have an atheroprotective effect.
Arteriosclerosis is arterial stiffening involving the entire
arterial tree, although it principally affects the elastic
arteries. Unlike atherosclerosis, arteriosclerosis involves
both intimal and medial thickening. In CKD, arterioscle-
rosis can occur in the absence of significant atherosclerotic
disease [67–69]. Arteriosclerosis is associated with vascular
remodeling characterized by increased wall thickness,
lumen enlargement and increased length of arteries. This
leads to an increase of systolic BP and pulse pressure and
arterial stiffening.
The triggers for vascular calcification are complex and
include metabolic, mechanical, infectious and inflammatory
injuries. Increased calcium x phosphate ion product or
hyperphosphatemia may be the key promoter of vascular
calcification [70]. The mechanisms include either stimula-
tion of the uptake and precipitation of calcium and
phosphate into the vessel or a decrease of the inhibitory
process that prevents these ions from precipitation. Fetuin-
A, the anti-inflammatory protein, is a highly potent
inhibitor of serum calcium-phosphate complex formation
[71, 72]. The serum concentrations of Fetuin-A are
decreased in ESRD patients [73]. Another promoter of
vascular calcification is 1,25(OH)2D3, which may have a
direct effect on the calcium deposition in vascular smooth
muscle cells [74]. In a comprehensive review, Vattikuti and
Towler [75] defined four major histo-anatomic variants of
vascular calcification, including classic atherosclerotic
(fibrotic) calcification related to disorders of lipid metabo-
lism, medial arterial calcification, vascular calcifilaxis and
cardiac valve calcification.
Spectrum of cardiovascular abnormalities in children
with CKD
Over the last decade, abnormalities of the LV such as LVH
and LV dysfunction, abnormalities of the large arteries such
as stiffness and increased intima-medial thickness (IMT) of
the carotids, and calcification of the coronaries have been
accepted as early markers of cardiomyopathy and athero-
sclerosis. They constitute strong independent predictors of
cardiac morbidity and mortality both in the general
population and in adults with CKD. In children and young
adults with CKD, recent studies have proven that these
abnormalities are also present and that risk factors for
cardiac and vascular injury in children with CKD are
similar to those for adults.
Left ventricular hypertrophy
LVH develops when renal insufficiency, is mild or moderate
in children and progresses as renal function deteriorates.
About one third of children with mild to moderate renal
insufficiency have an increased left ventricular mass (LVM)
index [76–78]. In a 2-year prospective longitudinal study of
31 pediatric subjects with CKD stage 2–4, Mitsnefes et al.
[79] showed that a substantial proportion of children had a
significant increase in the LVM index, with many of the
children developing LVH. Indeed, 32% of the patients who
initially had a normal LVM index have developed incident
LVH. At initiation of maintenance dialysis, 69–82% of
pediatric patients have evidence of LVH [80, 81]. LVH
persists (40–75%) during long-term dialysis [8, 76, 82–85],
with both concentric and eccentric geometric patterns of
LVH present in these patients. Post-mortem studies con-
firmed high rate (more than 50%) of LVH in children with
ESRD [86]. Small retrospective studies also suggest that
with a better BP and volume control, LVH regression might
be achieved in young patients on dialysis [80, 81]. On the
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LVH remains very prevalent and severe in a selected group
of children who remained on maintenance dialysis for at
least 2 years [9].
As in children prior to transplantation, most pediatric
studies indicate that LVH remains common post transplant
(48–82%) [87–91]. In contrast, a significantly lower
frequency of LVH was found in a study by Englund et al.
[92], who reported the results of a longitudinal analysis of
children receiving renal transplants 10–20 years ago. Of 53
children who received a renal transplant between 1981 and
1991, 47 survived and were observed for 10 to 20 years. At
the 10-year follow-up, echocardiography showed minor
LVH in only two children with hypertension. No child
without hypertension at 10 years post transplant had LVH.
The factors associated with cardiac hypertrophy in
children are similar to those in adults with CKD. As in
adults, most pediatric studies of patients with pre-terminal,
terminal renal failure and post transplant found significant
relationships between low hemoglobin and an increased
LVM index [8, 78, 79, 90]. However, recent adult studies in
mild to moderate CKD or in chronic dialysis determined
that correction of anemia was not associated with regression
of LVH [93–96]. Authors suggested that relationships
between anemia and LVH might not be causal. Of note,
the above studies enrolled subjects with relatively mild
degrees of baseline anemia and could not answer the
question whether treatment of patients with initially
significantly decreased hemoglobin levels might lead to a
reduction of LVM. In contrast, Morris et al. [97] observed a
significant reduction in the LVM index with the correction
of severe anemia in seven children on chronic dialysis.
There are several studies on the association between
parathyroid hormone (PTH) levels and LVH in adults with
CKD [98, 99]. In children, elevated PTH is associated with
progression of LVH in stages 2–4 CKD [79]. The possible
mechanisms of parathyroid-induced cardiac hypertrophy in
CKD include a direct effect of PTH on cardiomyocytes and
an indirect effect via elevated BP [99]. A support for a
causal relationship comes from in vitro studies showing that
PTH appears to have chronotropic, inotropic as well as
hypertrophic effects on cardiomyocytes [100, 101].
In adults with CKD, hypertension is directly linked to
the development of LVH [39]. The relationships between
BP and LVH in pediatric CKD are unclear. Consistent
correlations of LVM and BP are limited to children with
ESRD [8, 85]. However, a detailed cross-sectional analysis
of BP characteristics by ambulatory blood pressure moni-
toring (ABPM) in children from the ESCAPE trial did not
demonstrate any relationship between office BP or ABPM
parameters and LVM, suggesting only a minor role of
hypertension in the pathogenesis of LVH in early CRI [78].
In contrast, analysis of longitudinal data suggests that
ABPM might be an important tool to assess the risk of
development of LVH in children with CKD [79]. In this
study, authors determined that an increase in the nighttime
systolic BP load (number of BP measurements above the
95th percentile BP value) were independently associated
with the increase in the LVM index over time, arguing that
persistent and chronic elevation of BP might be more
important in the development of LVH [79].
Left ventricular function
In contrast to adults, in whom systolic dysfunction is
frequently associated with early cardiac failure and de-
creased survival, in children with CKD systolic LV function
is usually preserved [76, 102–104]. On the other hand,
diastolic dysfunction, often the initial abnormality of
cardiac function, is already present in children with CKD.
Doppler measurement of mitral inflow velocity has been
the most widely used method to assess LV diastolic
function. Using this method, Goren et al. [103] showed
that LV relaxation (E/A ratio) was impaired in dialyzed
children as compared to controls. Johnstone et al. [76] also
found a reduction in the E/A ratio in children on chronic
peritoneal dialysis and with pre-terminal renal failure,
although none of these patients had an E/A ratio <1.0,
which is considered to be abnormal. Unfortunately, the
transmitral Doppler velocities and, therefore, the E/A ratio,
are affected by several factors, including left atrial pressure
and preload. This is particularly important for patients with
advanced chronic renal failure, since many of them are
hypervolemic. Recently, new indices were introduced to
evaluate diastolic function using tissue Doppler imaging
(TDI). In contrast to E/A, the TDI indices may be less load
dependent and provide a more accurate measure of diastolic
function. Recent studies employing TDI determined that
children with CKD might have abnormal diastolic function
[105, 106]. In these studies, children on chronic dialysis
had significantly worse diastolic dysfunction than children
with mild-to-moderate CRI or post transplant. Poor diastol-
ic function in patients on dialysis was associated with
anemia, hyperphosphatemia, increased calcium-phosphorus
ion product and LVH. The clinical significance of diastolic
dysfunction in pediatric patients with CKD is not known.
Longitudinal studies are necessary to determine if abnormal
diastolic function predicts the development of systolic
dysfunction and congestive heart failure in these patients.
Arterial structure and compliance
Studies of young adults who developed ESRD during child-
hood found a high prevalence of abnormal carotid IMT,
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calcification (CAC). These vascular abnormalities are
accepted as markers of asymptomatic atherosclerosis and
predictors of future symptomatic CVD in the general
population and in adults with CKD [107, 108]. Groothoff
et al. [109] found increased arterial stiffness and showed that
systolic hypertension was the main determinant of abnormal
arterial wall compliance. Goodman et al. [110] showed that
among 23 patients on chronic dialysis who were younger
than 20 years of age, none had evidence of CAC; in
contrast, 14 of the 16 patients who were 20 to 30 years of
age had evidence of CAC on CT scanning. Oh et al. [3]
screened for coronary and carotid artery disease in 39
patients, aged 19 to 39 years, with childhood onset ESRD.
Coronary artery calcification was present in 92% and carotid
IMT was significantly increased compared to matched
controls. Carotid IMT was correlated with cumulative
dialysis and serum Ca x P product in their study. Milliner
et al. [111], in an autopsy study of pediatric patients with
ESRD who died in 1960–1983, showed a high prevalence
of soft tissue and vascular calcinosis. In their study, CAC
was present in 28%. Peak Ca x P product, peak serum P and
cumulative dose of calcitriol were significantly associated
with the severity of the calcinosis. Civilibal et al. [112]
screened 53 children with ESRD for the presence and
predisposing factors of CAC. Coronary artery calcification
was present in 15% of patients (three hemodialysis patients,
three peritoneal dialysis patients and two renal transplant
recipients). The patients with CAC had a longer duration of
total dialysis, had higher time-integrated serum phosphorus,
calcium-phosphate product, intact parathyroid hormone,
vitamin B12 levels and the amount of cumulative calcium-
containing oral phosphate binders. In a study by Briese et al.
[113] of 40 young adults (mean age 23.6 years) who
developed ESRD at a mean age of 11.5 years, carotid artery
IMT was similar to healthy controls and only 4 (10%)
patients had evidence of coronary calcification. Authors
noticed that a relatively low rate of cardiac calcification
compared to other studies might be explained by a
significantly lower amount of prescribed calcium-containing
phosphate binders and vitamin D preparations in their
patients. Of note, these patients had decreased vascular
reactivity and a high rate of LVH (68.2%). As in adults,
cardiac valve calcification was also described in children on
maintenance dialysis [114].
Evidence of early atherosclerotic changes was found in
the study by Nayir et al. [115], who reported on the
histopathology of internal iliac artery samples obtained at
the time of kidney transplantation in 12 children. Five
arteries had fibrous or fibroelastic intimal thickening,
medial mucoid ground substance and disruption of the
internal elastic lamella. Two of these had microcalcification
in the intimal layer; another two demonstrated atheroma-
tous plaques. These abnormalities were associated with
longer duration of renal failure.
Vascular abnormalities in children develop in parallel
with cardiac abnormalities early in the course of CKD and
become more severe as end-stage disease is reached [116].
Mitsnefes et al. [54] showed that carotid arteriopathy is
present in children after successful renal transplantation and
is associated with hypertension. Litwin et al. [117], as a part
of the ESCAPE trial, investigated vascular structure and
function in children with chronic renal failure and after renal
transplantation. The authors demonstrated vascular abnor-
malities in all patient groups with the most marked changes
in the dialysis patients. The degree of arteriopathy in their
study was correlated with conventional CVD risk factors
such as hypertension and dyslipidemia in pre-dialytic CKD,
while in children on dialysis and after transplantation,
hyperphosphatemia, hyperparathyroidism and treatment with
calcium-containing phosphate binders were determinants of
arterial abnormalities. Another important observation in this
study was a significantly lower carotid IMT in children post
transplant, suggesting that the vascular abnormalities par-
tially regress. Epidemiological studies should determine if
vascular abnormalities detected during childhood CKD are
associated with future accelerated coronary artery disease.
Endothelial dysfunction as a marker of early
atherosclerosis in children with CKD
Endothelial function can be evaluated by the assessing of
endothelial vasodilatation. Healthy vascular endothelium
will respond to the release of nitric oxide by vasodilatation.
With endothelial injury, the response to nitric oxide is
diminished [118], and endothelial-mediated vasodilatation
is impaired. Flow-mediated dilation (FMD) of the brachial
artery is currently used to measure endothelial function.
This test consists of applying obstruction to the flow of the
brachial artery by placing the tourniquet or inflated BP cuff
for few minutes. The artery dilates due to post-obstruction
reactive hyperemia. FMD is calculated based on the
difference in the diameter of the brachial artery before
obstruction and after it released. Impaired (decreased) FMD
predicts CVD morbidity and mortality in adults with ESRD
[119]. It has been shown that endothelial dysfunction as
determined by impaired FMD is also present in children
with advanced renal failure, on chronic dialysis and after
renal transplantation [120–122].
Evaluation and treatment recommendations
The overall strategy in the prevention of cardiovascular
complications in children with CKD is avoidance of long-
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delay the progression of cardiomyopathy and atherosclero-
sis. The identification of modifiable risk factors and
markers of CVD and early intervention should be initiated
at the time of mild-to-moderate renal insufficiency, prior to
the need for dialysis. Even though kidney transplantation
poses a continuous CV risk (hypertension, hyperlipidemia
and allograft dysfunction), it eliminates many uremia-
related risks, reduces the risk of cardiac death by
approximately 80 percent and prolongs the life span by
20–30 years. Thus, kidney transplantation should be the
ultimate goal to minimize cardiovascular morbidity and
mortality in patients with advanced CKD. For those
patients who must have long-term dialysis, the strategy is
directly linked to achievement of optimal dialysis out-
comes, which include aggressive monitoring and manage-
ment of hypertension, dyslipidemia, calcium-phosphorus
metabolism, anemia, nutrition, systemic inflammation and
other dialysis complications.
Current recommendations on evaluation of CV abnor-
malities and treatment of modifiable risk factors in children
are based mostly on clinical experience and adult data.
Recent K/DOQI Clinical Practice Guidelines for Cardio-
vascular Disease in Dialysis Patients [42] recommend
echocardiographic evaluation for the presence of cardiac
disease in children (cardiomyopathy and valvular disease)
at the time of initiation of dialysis therapy along with the
screening for dyslipidemia, hypertension, anemia and
increased Ca×P product. Management of modifiable risks
in children with CKD should follow recommendations from
the K/DOQI guidelines for treatment of anemia [123] and
dyslipidemia [15] and from the Fourth Report on Blood
Pressure in Children for Management of Hypertension
[124]. Current K/DOQI guidelines for treatment of anemia
recommend keeping the hemoglobin level above 11 g/dl by
using an appropriate iron therapy and recombinant eryth-
ropoietin. In the opinion of the Working Group, there is
insufficient evidence to recommend routinely maintaining
hemoglobin levels above 13 g/dl or more.
K/DOQI recommends evaluation of dyslipidemia in
adolescents upon presentation with CKD stage 5 (GFR
<15 ml/min/1.73 m
2 or on dialysis), at 2–3 months after a
change in treatment or other conditions known to cause
dyslipidemia and at least annually thereafter. Reasons to
repeat lipid measurements after 2–3 months include
changes in the kidney replacement therapy modality,
treatment with diet or lipid-lowering agents, immunosup-
pressive agents that affect lipids (e.g., prednisone, cyclo-
sporine or sirolimus) or other changes that may affect
plasma lipids. The assessment of dyslipidemia should
include a complete fasting lipid profile with total choles-
terol, LDL, HDL and triglycerides. The definition of
dyslipidemia differs in children and adults. Hyperlipidemia
in children is defined as lipid levels greater than the 95th
percentile for age and gender. The normative data for lipids
in children and adolescents currently used are from the
Lipid Research Clinics Program from the NIH published in
1980 and can be found in the 2003 K/DOQI guidelines for
management of dyslipidemia in chronic kidney disease [15].
For adolescents with stage 5 CKD and a level of LDL
≥130 mg/dl, K/DOQI recommends treatment to reduce
LDL to <130 mg/dl. If LDL is <130 mg/dl, fasting
triglycerides ≥200 mg/dl and non-HDL cholesterol (total
cholesterol minus HDL) ≥160 mg/dl, treatment should be
considered to reduce non-HDL cholesterol to <160 mg/dl.
All children with dyslipidemia should follow the recom-
mendations for therapeutic lifestyle changes (TLC), which
include diet modification with a reduction in saturated fat
intake and increase in fiber intake, and moderate physical
activity. Adolescents should be counseled about avoiding
smoking. Unfortunately, non-compliance with TLC is one
of the major problems in the management of dyslipidemia
in adolescents. Pediatric nephrologists must also recognize
that appropriate caloric intake, including calories from fat,
should be emphasized to avoid malnutrition and ensure
normal growth and development, especially in young
children. If LDL cholesterol is ≥160 mg/dl and non-HDL
cholesterol ≥190 mg/dl, statin therapy is recommended in
children older than 10 years.
Target blood pressure in children should be lower than the
90th percentile for normal values adjusted for age, gender
and height or less than 120/80 mm Hg, whichever is lower.
Ambulatory blood pressure monitoring is recommended to
assess the circadian rhythm. Angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers may be the
preferred antihypertensive agents to slow the progression
of CKD in children and possibly for regression of LVH. The
Working Group on Cardiovascular Disease in Dialysis
Patients recommends maintaining calcium and phosphorus
levels within the normal range and the Ca×P product
<55 mg
2/dl
2 in children on chronic dialysis [42].
There are no data available to make evidence-based rec-
ommendations on management of hyperhomocysteinemia,
chronic inflammation or other potential CVD risk factors.
Questions
(Answers appear following the references)
1. A 14-year-old African-American boy with ESRD
secondary to FSGS has been treated with thrice-weekly
hemodialysis for 1 year. His pre-dialysis BP is 132/85,
hemoglobin is 9.8 g/dl, serum calcium is 10.6 g/dl,
serum phosphorus is 8.2 g/dl and iPTH is 412 pg/ml.
He is taking a calcium channel blocker to control his
hypertension, erythropoietin and iron to control his
anemia and calcium carbonate and a vitamin D IV
preparation to control his renal bone disease.
34 Pediatr Nephrol (2008) 23:27–39Which ONE of the following statements would be the
BEST therapeutic intervention in this child to minimize
the risk of future CV complications?
a. Aggressive treatment of hypertension
b. Maximize dialysis treatment to achieve dry weight
c. Correction of anemia
d. Kidney transplantation
e. Reduction of Ca-P product
2. The patient from the previous question was diagnosed
with eccentric LVH.
With regard to treatment of his LVH, which ONE of
the following actions is MOST LIKELY to lead to
reduction of LVH?
a. Adding ACE inhibitor as a second antihypertensive
agent
b. Increase the dose of erythropoietin and assure
appropriate iron status to treat anemia
c. Achievement of dry weight
d. Switch from hemodialysis to peritoneal dialysis
e. Maximize treatment of secondary hyperparathy-
roidism
3. The annual evaluation showed that this patient has LDL
cholesterol of 170 mg/dl. You would like to start this
patient on atorvastatin.
With regard to the use of “statin” in this patient,
which ONE of the following statements is correct?
a. Statins are not approved by the United States Food
and Drug Administration (USFDA) for use in
children and adolescents
b. Grapefruit is contraindicated
c. The dose of atorvastatin should be reduced by 50%
compared to dosage in adult patients on dialysis to
prevent adverse effects on growth and development
d. The target level for LDL cholesterol in children
with CKD should be below 100 mg/dl
e. Atorvastatin therapy will reduce mortality risk in
this patient
4. Which ONE of the following statements concerning
development of cardiovascular complications in a
child with CKD is NOT correct?
a. Cardiovascular disease is the cause of mortality in
approximately 25% of chronically dialyzed children
b. Cardiac arrest is the most common cardiac cause of
death in children with ESRD
c. Cardiac and vascular remodeling might develop in
children during early stages of CKD
d. Correction of anemia reduces concentric LVH
e. LVH is the most common cardiac abnormality in
children on maintenance dialysis
5. The patient described in the previous questions is at
risk for development of vascular calcification.
Which ONE of the following choices does NOT
correctly describe the mechanisms of vascular calcifica-
tion in dialyzed patients?
a. Histo-anatomic variants of calcification include
classic atherosclerotic (fibrotic) calcification related
to disorders of lipid metabolism, medial arterial
calcification, vascular calcifilaxis and cardiac valve
calcification
b. Increased Ca-P product and hyperphosphatemia are
the key drivers of vascular calcification in young
patients with CKD
c. Inflammatory mechanisms are involved in mediating
all stages of atherosclerosis including calcification
d. Increased serum level of Fetuin-A promotes Ca-P
ion product precipitation
e. 1,25 (OH)2D3 increases calcium deposition in the
vascular wall
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